Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | NCK1 | P16333 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14764426 | 0.89 | NQO2 (0.57) | NQO2ALDH1A1KDM4EL3MBTL1KMT2A | |
| SCHEMBL14764615 | 0.89 | NQO2 (0.57) | NQO2ALDH1A1KDM4EL3MBTL1KMT2A | |
| SCHEMBL1138054 | 0.86 | NQO2 (0.53) | NQO2ALDH1A1KDM4EL3MBTL1KMT2A | |
| SCHEMBL13077444 | 0.86 | NQO2 (0.53) | NQO2ALDH1A1KDM4EL3MBTL1KMT2A | |
| SCHEMBL2756741 | 0.85 | NQO2 (0.85) | NQO2ALDH1A1KDM4EL3MBTL1MAPT | |
| SCHEMBL9927345 | 0.85 | NQO2 (0.85) | NQO2ALDH1A1KDM4EL3MBTL1MAPT | |
| SCHEMBL20049288 | 0.82 | ALDH1A1 (0.50) | NQO2ALDH1A1KDM4EL3MBTL1KMT2A | |
| SCHEMBL29340312 | 0.82 | PGK1 (0.57) | NQO2ALDH1A1KDM4EL3MBTL1KMT2A | |
| SCHEMBL4928778 | 0.82 | NQO2 (0.50) | NQO2ALDH1A1KDM4EL3MBTL1KMT2A | |
| SCHEMBL29340314 | 0.82 | PGK1 (0.57) | NQO2ALDH1A1KDM4EL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798283-A | All-organic water system zinc ion battery positive electrode material and preparation method and application thereof | 石河子大学 | 2025-04-11 | — | — | CN | claimed |
| US-20090274967-A1 | QUINOXALINE CONTAINING PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-11-05 | — | — | US | claimed |
| EP-0266662-B1 | PROCESS FOR THE PREPARATION OF POLY(ARYLENSULPHIDES) WITH LOWER CRYSTALLIZATION TEMPERATURE | BAYER AG (DE) | 1992-06-10 | — | — | EP | claimed |
| US-4824933-A | DIMENSIONAL STABILITY, CHEMICAL RESISTANT | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-25 | — | — | US | claimed |
| EP-0266662-A2 | Process for the preparation of poly(arylensulphides) with lower crystallization temperature | BAYER AG (DE) | 1988-05-11 | — | — | EP | claimed |
| CN-119798283-A | All-organic water system zinc ion battery positive electrode material and preparation method and application thereof | 石河子大学 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025021868-A1 | TRAF2 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2025-01-30 | — | — | WO | disclosed |
| WO-2022202643-A1 | METHOD FOR PRODUCING S,S-(6-METHYLQUINOXALINE-2,3-DIYL)DITHIOCARBONATE | 株式会社大阪ソーダ | 2022-09-29 | — | — | WO | disclosed |
| US-11299634-B2 | Reactive leuco compounds and compositions comprising the same | MILLIKEN & COMPANY (US) | 2022-04-12 | — | — | US | disclosed |
| CN-107935944-B | Diaryl urea quinoxaline derivative with anti-tumor activity and synthetic method thereof | 广西师范大学 | 2021-12-21 | — | — | CN | disclosed |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| EP-0095637-A2 | Process for preparing alpha-chlorinated nitrogen heterocycles | BAYER AG (DE) | 1983-12-07 | — | — | EP | disclosed |
| EP-0045423-A1 | Process for the alpha-halogenation of possibly substituted methyl aromatics | BAYER AG (DE) | 1982-02-10 | — | — | EP | disclosed |
| US-4200748-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-04-29 | — | — | US | disclosed |
| US-4184977-A | WHITENING | BAYER AKTIENGESELLSCHAFT (DE) | 1980-01-22 | — | — | US | disclosed |
| EP-0000346-B1 | QUINOXALINE COMPOUNDS, PROCESS FOR THEIR MANUFACTURE AND THEIR USE AS BRIGHTENERS FOR ORGANIC MATERIALS, AND THE MATERIALS BRIGHTENED THEREWITH | BAYER AG (DE) | 1980-01-09 | — | — | EP | disclosed |
| EP-0000346-A1 | Quinoxaline compounds, process for their manufacture and their use as brighteners for organic materials, and the materials brightened therewith | BAYER AG (DE) | 1979-01-24 | — | — | EP | disclosed |
| US-4025510-A | DYES FOR POLYESTERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
| US-3988455-A | Ditetrazolo(1,5-a:5',1'-c)quinoxalines for control of soil-borne phytopathogens | ELI LILLY AND COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | BRD4, BET1, BRD3 | NQO2 486/4885ALDH1A1 4699/4885KDM4E 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.